A Phase 4 interventional study of Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®) and Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®) in Infertility, sponsored by Nanjing University. Not yet recruiting at 1 site in China. Open to female participants aged 35 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-08-27.
Sponsored by Nanjing University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing follitropin alfa in Infertility — 3 open to participants now, 4 under way, 1 of them phase 3. follitropin alfa · Infertility.
Among the 30 studies testing follitropin alfa in Infertility, this one is the 6th largest by planned enrollment, is the only one that started in 2024, is one of 13 in phase 4, and was the 27th registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →3 of the 30 studies testing follitropin alfa in Infertility are open now, in 3 countries. Recruiting first, the newest first:
Vietnam Military Medical University · Sites in Vietnam
Ages 18–34 · Women only
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Sites in Japan
Ages 18–42 · Women only
By country, each count listing its studies:
follitropin alfa: first FDA approval 1997 (Gonal-f), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 35 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 133 across 1,415 interventional studies indexed under Infertility.
Median enrollment 159 across the 30 interventional studies. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 30 have an industry lead sponsor. The 10 most frequent:
Nanjing University is the lead sponsor of 21 studies on the registry; 9 are open to participants now.
Nanjing University has 4 studies filed under Infertility — fewer than ten, so there is no comparison to draw.
2 of the studies testing follitropin alfa in Infertility that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340827Phase 3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyA Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) | 2027-09-30 |
| NCT06571214Nanjing UniversityPotential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment | 2026-12-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies testing follitropin alfa in Infertility, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This will be an exploratory, prospective, randomized, open-label and controlled trial to evaluate the potential benefit of r-hFSH:r-hLH 2:1 co-treatment starting from COS D1 versus r-hFSH alone in patients aged 35 to 40 under ovarian stimulation treatment.
After signing informed consent form (ICF), all eligible participants will be randomly assigned in a 1:1 ratio to either treatment or control group, and GnRH antagonist protocol will be used in both treatment and control groups.
This will be an exploratory, prospective, randomized, open-label and controlled trial to evaluate the potential benefit of r-hFSH:r-hLH 2:1 co-treatment starting from COS D1 versus r-hFSH alone in patients aged 35 to 40 under ovarian stimulation treatment.
After signing informed consent form (ICF), all eligible participants will be randomly assigned in a 1:1 ratio to either treatment or control group, and GnRH antagonist protocol will be used in both treatment and control groups.
The estimated treatment duration is 11 days from the first day of COS until 24\~48 h prior to trigger drug injection, and this may vary depending on individual circumstances.
Follicular development, serum E2 and P levels will be monitored during COS according to the investigator site's ART practice until the criteria to administer trigger drug are met to induce final oocyte maturation. Trigger drug administration is to be performed according to the site's routine clinical practice.
Oocyte pick-up (OPU), IVF/ICSI, ET, and luteal phase support (LPS) will be performed according to the site's routine practice. LPS will be started after oocyte retrieval in fresh embryo transfer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The r-hFSH starting dose will be based on the patient's profile and physician's experience. r-hLH will be added at a ratio of 2:1 starting from day 1 of r-hFSH administration; the dose of r-hFSH during COS will be adjusted by the physician based on clinical experience and the patient's ovarian response, and the r-hFSH: r-hLH dose will be 2:1, continuing to 24\~48 hours prior to trigger drug injection. For both groups, daily injection of 0.25 mg of cetrorelix (Cetrotide®, Merck Serono S.A.) will be administrated subcutaneously when at least one follicle with diameter ≥ 14 mm or serum LH level exceeds 10 IU/L or LH level is 2 folder than basal LH level or P level exceeds 0.8 ng/ml, continuing until ovulation triggering day. Cetrorelix can be administrated earlier in patients with advanced age or diminished ovarian reserve according to judgment of clinicians.
Drug: Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®) · Drug: Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)
r-hFSH alone will be administrated for ovarian stimulation. The r-hFSH starting dose will be based on the patient's profile and physician's experience. The dose of r-hFSH during COS will be adjusted by the physician based on clinical experience and the patient's ovarian response, continuing to 24\~48 hours prior to trigger drug injection. For both groups, daily injection of 0.25 mg of cetrorelix (Cetrotide®, Merck Serono S.A.) will be administrated subcutaneously when at least one follicle with diameter ≥ 14 mm or serum LH level exceeds 10 IU/L or LH level is 2 folder than basal LH level or P level exceeds 0.8 ng/ml, continuing until ovulation triggering day. Cetrorelix can be administrated earlier in patients with advanced age or diminished ovarian reserve according to judgment of clinicians.
Drug: Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)
As a r-hFSH agent, Gonal-f® is used for COS. It is a prefilled ready to use pen device containing follitropin alfa for injection and is designed for subcutaneous self-administration by patients undergoing COS for ART. It is available as dose presentations of 150 IU and 450 IU. The investigators and/or his/her delegate/s will explain the use of Gonal-f® prefilled pen. Gonal-f® will be prescribed by the investigator based on clinical diagnosis and treatment routines, and will not be provided free of charge.
This product is a white freeze-dried powder and a colorless and clear injection solvent, and stored away from light under 25℃ in the original packaging. Luveris® will be provided free of charge.
Good quality embryo rate (cleavage stage)
Cleavage stage good-quality embryos are defined as embryos derived from normally fertilized zygotes with 7\~9 cells on day 3 post-fertilization, stage-specific cell size, less than 10% fragmentation, and no multinucleation. Cleavage stage good-quality embryo rate is defined as the number of cleavage stage good-quality embryos divided by the number of normally fertilized zygotes. Embryos will be assessed by two independent experienced embryologists to minimize intra-observation variability.
Time frame: Day 3 after fertilization
Number of oocytes
Number of oocytes is defined as the total number of oocytes obtained through transvaginal ultrasound guided puncture on the day of OPU. All follicles with an estimated diameter of ≥12 mm should be punctured.
Time frame: 24 hours after Oocytes pick up
Number of MII oocytes (analyzed in ICSI subgroup only)
Number of MII oocyte is defined as the total number of an oocyte at metaphase of meiosis II, exhibiting the first polar body and with the ability to become fertilized
Time frame: 24 hours after Oocytes pick up
Total r-hFSH dose
Total r-hFSH dose is defined as the total dose of r-hFSH used for subcutaneous injection during COS period.
Time frame: 24 hours after ovulation triggering
Fertilization rate
* IVF normal fertilization rate is defined as the number of oocytes with 2PN and 2PB divided by the number of COCs inseminated. * ICSI normal fertilization rate is defined as the number of oocytes with 2PN and 2PB divided by the number of MII oocytes injected.
Time frame: 24 hours after fertilization
Blastocyst development rate
Blastocyst development rate is defined as the proportion of blastocysts observed at 116 ± 2 h post-insemination as a function of the number of normally fertilized oocytes.
Time frame: 5 days after fertilization, up to 7 days
Utilizable embryo rate
Utilizable embryo rate is defined as the number of embryos (or blastocysts) suitable for transfer or cryopreservation as a function of the number of normally fertilized (2PN) oocytes observed on Day 1.
Time frame: 5 days after fertilization, up to 7 days
Implantation rate
Implantation rate is defined as the number of gestational sacs observed divided by the number of embryos transferred using transvaginal ultrasound 4\~6 weeks after embryo transfer.
Time frame: At 4-6 weeks of amenorrhea after customized timing of embryo transfer
Clinical pregnancy rate (per transfer cycle and per oocyte retrieval cycle)
Clinical pregnancy rate is defined as the number of clinical pregnancies expressed per 100 initiated cycles, aspiration cycles, or embryo transfer cycles. Clinical pregnancy is defined as the presence of gestational sac (intrauterine or ectopic) using ultrasound examination at 4\~6 weeks after embryo transfer.
Time frame: At 4-6 weeks of amenorrhea after customized timing of embryo transfer
Ongoing pregnancy rate
Ongoing pregnancy rate is defined as the number of intrauterine pregnancies continued for 12 gestational weeks divided by the number of embryo transfer cycles.
Time frame: At 12 weeks of amenorrhea after customized timing of embryo transfer
Ovarian sensitivity index (OSI)
OSI is defined as the total r-hFSH dose divided by the number of oocytes retrieved.
Time frame: 24 hours after fertilization
Follicular output rate (FORT)
FORT is defined as the number of pre-ovulatory follicles (16\~22 mm) on the day of trigger divided by the AFC (3\~8 mm)
Time frame: 24 hours after fertilization
Follicle oocyte index (FOI)
FOI is defined as the number of total oocytes retrieved divided by the AFC
Time frame: 24 hours after fertilization
Safety Assessments
AE, SAE and OHSS
Time frame: During the COS cycle (average cycle range 11 days), Up to 12 weeks after transfer
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2024; primary completion for Dec 2026, 27 months later.
Of 74 non-industry phase 4 interventional studies under Infertility, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's planned 27 months is below that.
Counting every sponsor, half of 81 studies reached it within 33 months; a quarter within 19 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin alfa
Nanjing University